First quarter TRCV* increased 13% year-over-year to
Cash flow from operations increased 8% year-over-year to
"We delivered a strong start to 2026, with record Total Recurring Contract Value and our first quarter of year-over-year revenue growth since 2023, reflecting the tangible momentum building across our business,” said
First Quarter 2026 Highlights
- Revenue: Total revenue was
$34.8 million for the three months endedMarch 31, 2026 , up 4% from the prior year - Net Income: GAAP net income was
$3.2 million , representing 9% of revenue, and Adjusted Net Income* was$4.6 million , representing 13% of revenue - Adjusted EBITDA: Adjusted EBITDA* was
$9.4 million , representing 27% of revenue - Earnings Per Share: GAAP net income per fully diluted share was
$0.14 on 21.9 million fully diluted shares; Adjusted net income per diluted share* was$0.21 on 21.9 million fully diluted shares - Cash Flow: Net cash flow from operating activities was
$7.2 million , representing 21% of revenue; Free cash flow* was$5.4 million , representing 15% of revenue - TRCV: Total Recurring Contract Value (TRCV)* was
$152.1 million , up 13% year-over-year, and grew sequentially for the sixth consecutive quarter
* These financial measures are defined below under the headings “Non-GAAP Financial Measures” and “Total Recurring Contract Value.” Reconciliations of the non-GAAP measures to their most closely comparable GAAP measures are included in the tables in this release.
Dividend Declaration
The Company’s Board of Directors on
Earnings Call Information
The company will be hosting a conference call to discuss the financial results on
About
For more than 45 years,
Total Recurring Contract Value
Total Recurring Contract Value, or TRCV, is viewed by management as a leading indicator of our future revenue trends. It represents the total annualized contract value under customer contracts that are in effect or contractually committed as of the most recent quarter-end, based on contractual pricing and term provisions, and expected to be in force over the subsequent 12 months. TRCV is an operating metric and is not a measure of revenue recognized under
Non-GAAP Financial Measures
In addition to consolidated GAAP financial measures,
There is no comprehensive, authoritative guidance for the presentation of such non-GAAP information, which is only meant to supplement GAAP results by providing additional information that management utilizes to assess performance.
Forward-Looking Statements
This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements may be identified by their use of terms or phrases such as “believes,” “expect,” “focus,” “potential,” “will,” derivations thereof, and similar terms and phrases. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements, including those risks and uncertainties as set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended
NRC HEALTH Condensed Consolidated Statements of Income (In thousands except per share data, unaudited) | ||||||||
|
| Three months ended |
| |||||
|
| 2026 |
|
| 2025 |
| ||
|
|
|
|
|
|
|
|
|
Revenue |
| $ | 34,803 |
|
| $ | 33,551 |
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Direct |
|
| 13,646 |
|
|
| 13,057 |
|
Selling, general, and administrative |
|
| 13,419 |
|
|
| 10,356 |
|
Depreciation and amortization |
|
| 2,169 |
|
|
| 1,542 |
|
Total operating expenses |
|
| 29,234 |
|
|
| 24,955 |
|
|
|
|
|
|
|
|
|
|
Operating income |
|
| 5,569 |
|
|
| 8,596 |
|
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
Interest income |
|
| 35 |
|
|
| 19 |
|
Interest expense |
|
| (1,255 | ) |
|
| (899 | ) |
Other, net |
|
| 30 |
|
|
| 7 | |
|
|
|
|
|
|
|
|
|
Total other expense |
|
| (1,190 | ) |
|
| (873 | ) |
|
|
|
|
|
|
|
|
|
Income before income taxes |
|
| 4,379 |
|
|
| 7,723 |
|
|
|
|
|
|
|
|
|
|
Provision for income taxes |
|
| 1,157 |
|
|
| 1,936 |
|
|
|
|
|
|
|
|
|
|
Net income |
| $ | 3,222 |
|
| $ | 5,787 |
|
|
|
|
|
|
|
|
|
|
Earnings per share of common stock: |
|
|
|
|
|
|
|
|
Basic |
| $ | 0.14 |
|
| $ | 0.25 |
|
Diluted |
| $ | 0.14 |
|
| $ | 0.25 |
|
|
|
|
|
|
|
|
|
|
Weighted average shares and share equivalents outstanding: |
|
|
|
|
|
|
|
|
Basic |
|
| 21,799 |
|
|
| 22,972 |
|
Diluted |
|
| 21,911 |
|
|
| 22,974 |
|
NRC HEALTH Condensed Consolidated Balance Sheets (Dollars in thousands except share amounts and par value) | ||||||||
|
|
|
|
|
| |||
| (unaudited) |
|
|
|
|
| ||
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
| $ | 2,547 |
|
| $ | 4,139 |
|
Accounts receivable, net |
|
| 10,833 |
|
|
| 11,108 |
|
Other current assets |
|
| 6,604 |
|
|
| 4,962 |
|
Total current assets |
|
| 19,984 |
|
|
| 20,209 |
|
|
|
|
|
|
|
|
|
|
Property and equipment, net |
|
| 40,305 |
|
|
| 40,474 |
|
|
| 66,152 |
|
|
| 66,152 |
| |
Other, net |
|
| 8,118 |
|
|
| 8,043 |
|
Total assets |
| $ | 134,559 |
|
| $ | 134,878 |
|
|
|
|
|
|
|
|
|
|
Liabilities and Shareholders’ Equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Current portion of notes payable, net of unamortized debt issuance costs |
| $ | 4,015 |
|
| $ | 4,014 |
|
Accounts payable and accrued expenses |
|
| 4,809 |
|
|
| 4,066 |
|
Accrued wages and bonuses |
|
| 6,603 |
|
|
| 7,218 |
|
Deferred revenue |
|
| 17,192 |
|
|
| 16,201 |
|
Dividends payable |
|
| 3,606 |
|
|
| 3,625 |
|
Other current liabilities |
|
| 2,245 |
|
|
| 1,496 |
|
Total current liabilities |
|
| 38,470 |
|
|
| 36,620 |
|
|
|
|
|
|
|
|
|
|
Notes payable, net of current portion and unamortized debt issuance costs |
|
| 74,017 |
|
|
| 75,021 |
|
Other non-current liabilities |
|
| 8,577 |
|
|
| 9,247 |
|
Total liabilities |
|
| 121,064 |
|
|
| 120,888 |
|
|
|
|
|
|
|
|
|
|
Shareholders’ equity: |
|
|
|
|
|
|
|
|
Preferred stock, |
|
| -- |
|
|
| -- |
|
Common stock, |
|
| 32 |
|
|
| 32 |
|
Additional paid-in capital |
|
| 185,627 |
|
|
| 183,880 |
|
Retained earnings (accumulated deficit) |
|
| (17,682 | ) |
|
| (17,298 | ) |
|
| (154,482 | ) |
|
| (152,624 | ) | |
Total shareholders’ equity |
| $ | 13,495 |
|
| $ | 13,990 |
|
Total liabilities and shareholders’ equity |
| $ | 134,559 |
|
| $ | 134,878 |
|
NRC HEALTH Condensed Consolidated Statements of Cash Flows (In thousands, unaudited) | ||||||||
|
| Three months ended |
| |||||
|
|
| ||||||
|
| 2026 |
|
| 2025 |
| ||
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
Net income |
| $ | 3,222 |
|
| $ | 5,787 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
| 2,169 |
|
|
| 1,542 |
|
Deferred income tax expense |
|
| (36 | ) |
|
| 1,860 |
|
Reserve for uncertain tax positions |
|
| (56 | ) |
|
| 76 |
|
Non-cash share-based compensation expense |
|
| 1,608 |
|
|
| 171 |
|
Change in fair value of contingent consideration |
|
| - |
|
|
| 31 |
|
Loss on extinguishment of debt |
|
| - |
|
|
| 67 |
|
Amortization of debt issuance costs |
|
| 27 |
|
|
| 15 |
|
Net changes in assets and liabilities: |
|
|
|
|
|
|
|
|
Trade accounts receivable |
|
| 275 |
|
| (272 | ) | |
Prepaid expenses and other current and long-term assets |
|
| (1,627 | ) |
|
| (2,419 | ) |
Deferred contract costs, net |
|
| (625 | ) |
|
| 24 |
|
Operating lease assets and liabilities, net |
|
| (30 | ) |
|
| (26 | ) |
Accounts payable |
|
| 942 |
|
|
| 627 |
|
Accrued expenses, wages, and bonuses |
|
| (889 | ) |
|
| (472 | ) |
Income taxes receivable and payable |
|
| 1,265 |
|
| (80 | ) | |
Deferred revenue |
|
| 935 |
|
| (285 | ) | |
Net cash provided by operating activities |
|
| 7,180 |
|
|
| 6,646 |
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
Capital expenditures |
|
| (1,834 | ) |
|
| (2,986 | ) |
Net cash used in investing activities |
|
| (1,834 | ) |
|
| (2,986 | ) |
|
|
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
Borrowings on notes payable |
|
| - |
|
|
| 27,738 |
|
Payments on notes payable |
|
| (1,030 | ) |
|
| (28,724 | ) |
Borrowings on revolving loan |
|
| 2,500 |
|
|
| 8,000 |
|
Payments on revolving loan |
|
| (2,500 | ) |
|
| (4,503 | ) |
Payment of debt issuance costs |
|
| - |
|
| (62 | ) | |
Payments on finance lease obligations |
|
| (3 | ) |
|
| (2 | ) |
Proceeds from the exercise of share-based awards |
|
| 139 |
|
|
| 132 |
|
Payment of acquisition contingent consideration |
|
| (484 | ) |
|
| (280 | ) |
Repurchase of shares for treasury |
|
| (1,935 | ) |
|
| (4,920 | ) |
Payment of dividends on common stock |
|
| (3,625 | ) |
|
| (2,770 | ) |
Net cash used in financing activities |
|
| (6,938 | ) |
|
| (5,391 | ) |
|
|
|
|
|
|
|
|
|
Change in cash and cash equivalents |
|
| (1,592 | ) |
|
| (1,731 | ) |
Cash and cash equivalents at beginning of period |
|
| 4,139 |
|
|
| 4,233 |
|
Cash and cash equivalents at end of period |
| $ | 2,547 |
|
| $ | 2,502 |
|
NRC HEALTH Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands, except per share data, unaudited) | ||||||||
Adjusted Net Income and Adjusted Earnings per Share | ||||||||
|
| Three months ended |
| |||||
|
| 2026 |
|
| 2025 |
| ||
|
|
|
|
|
|
|
|
|
Net income |
| $ | 3,222 |
|
| $ | 5,787 |
|
Add back: |
|
|
|
|
|
|
|
|
Non-cash stock compensation |
|
| 1,608 |
|
|
| 171 |
|
Tax on stock compensation |
|
| (262 | ) |
|
| (43 | ) |
Adjusted net income |
| $ | 4,568 |
|
| $ | 5,915 |
|
Weighted average shares and share equivalents outstanding, diluted |
|
| 21,911 |
|
|
| 22,974 |
|
Adjusted earnings per share, diluted |
| $ | 0.21 |
|
| $ | 0.26 |
|
Adjusted EBITDA and Adjusted EBITDA Margin | ||||||||
|
| Three months ended | ||||||
|
| 2026 |
|
| 2025 |
| ||
|
|
|
|
|
|
| ||
Net income |
| $ | 3,222 |
|
| $ | 5,787 |
|
Add back: |
|
|
|
|
|
| ||
Depreciation and amortization |
|
| 2,169 |
|
|
| 1,542 |
|
Interest expense |
|
| 1,255 |
|
|
| 899 |
|
Income taxes |
|
| 1,157 |
|
|
| 1,936 |
|
Non-cash stock compensation |
|
| 1,608 |
|
|
| 171 |
|
Adjusted EBITDA |
| $ | 9,411 |
|
| $ | 10,335 |
|
Adjusted EBITDA margin |
|
| 27.0 | % |
|
| 30.8 | % |
Free Cash Flow and Free Cash Flow Margin | ||||||||
|
| Three months ended | ||||||
|
| 2026 |
|
| 2025 |
| ||
|
|
|
|
|
|
| ||
Net cash provided by operating activities |
| $ | 7,180 |
|
| $ | 6,646 |
|
Less: |
|
|
|
|
|
| ||
Capital expenditures |
|
| 1,834 |
|
|
| 2,986 |
|
Free cash flow |
| $ | 5,346 |
|
| $ | 3,660 |
|
Free cash flow margin |
|
| 15.4 | % |
|
| 10.9 | % |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260428087067/en/
Media Contact
marketing@nrchealth.com
Investor Contact
ir@nrchealth.com
Source: